Horizon Therapeutics initiates PROTECT trial evaluating KRYSTEXXA® (pegloticase injection)
Horizon Therapeutics announced it has initiated an open-label clinical trial evaluating use of KRYSTEXXA® (pegloticase injection) in adults with chronic gout refractory to conventional therapies who have undergone a kidney transplant to demonstrate KRYSTEXXA may provide effective disease control. October 17, 2019